Axel Wieandt

Outcome of Strategic Implementation Review and Directorate Change

Retrieved on: 
Friday, April 30, 2021
Given names, European culture, Axel Wieandt, Risk, Axël

Axel Wieandt and James Noble will no longer be joining the Board.\n"Arix has had a busy year and made significant progress.

Key Points: 
  • Axel Wieandt and James Noble will no longer be joining the Board.\n"Arix has had a busy year and made significant progress.
  • We believe it was incumbent upon us to lead on these issues at a critical time when the company was exposed to significant risk.
  • It will be held as soon as possible and, in any case, no later than 30 June 2021.
  • The person responsible for arranging for the release of this announcement on behalf of Arix is Robert Lyne, General Counsel Arix.\n'

Board update

Retrieved on: 
Monday, March 29, 2021
Articles, Business, Finance, Axel Wieandt, Entrepreneurship, Venture capital, Board of directors

LONDON, 29 March 2021: The board of Arix, (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, has paused its timetable to appoint James Noble and Axel Wieandt as non-executive directors of the Company.

Key Points: 
  • LONDON, 29 March 2021: The board of Arix, (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, has paused its timetable to appoint James Noble and Axel Wieandt as non-executive directors of the Company.
  • Whilst the board continues to believe that both appointees are highly qualified with relevant experience and expertise, it believes the appointments should be considered within the scope of the Company's recently announced Strategic Implementation Review, (the "Review") which includes the question of board composition.

Board Changes

Retrieved on: 
Thursday, February 25, 2021
Axel Wieandt

LONDON, 25 February 2021:Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that James Noble and Axel Wieandt will each be joining the Board as Non-Executive Directors, effective 1 April 2021.

Key Points: 
  • LONDON, 25 February 2021:Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that James Noble and Axel Wieandt will each be joining the Board as Non-Executive Directors, effective 1 April 2021.
  • The company also announces that Mark Breuer, Non-Executive Director, will step down from the Board on 1 April 2021, after serving on the Board for two years.
  • Naseem Amin, MD, Executive Chairman of Arix, commented: "We are delighted to announce that James and Axel are joining the Arix Board.
  • "On behalf of the Board, I would like to thank Mark Breuer for the commitment and invaluable support he has shown to the Company over the last two years."